1. Scrip
  2. >>Focus On Asia

Pfizer Sues Sandoz Over Lipitor Generics In Japan

Pfizer Inc. has filed an infringement lawsuit with Tokyo District Court over Lipitor (atorvastatin) generics marketed by Sandoz.

Pfizer Inc. has filed an infringement lawsuit with Tokyo District Court over Lipitor (atorvastatin) generics marketed by Sandoz. Pfizer said its patent over the crystal form of the best-selling cholesterol lowering agent are valid until July 2016, and requested the halt of manufacturing, marketing and import of atorvastatin in Japan. Since last November, five companies have launched atorvastin generics in Japan to compete with Lipitor. Pfizer only mentioned Sandoz, the largest generic atorvastatin seller, in the suit. (Click here for more – Japanese language

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges